Clinical Trial Update: Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares adding Zevalin to BEAM high-dose chemotherapy versus BEAM conditioning alone in chemosensitive relapsed non-Hodgkin's lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Alkeran (melphalan)
• BiCNU (carmustine)
• Cytosar-U (cytarabine)
• VePesid (etoposide)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Soroka University Medical Center | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: UNKNOWN